tucatinib,trastuzumab,trifluridine tipiracil,Bevacizumab,Botensilimab,balstilimab
roche,seagen,otsuka,taiho pharma,agenus
[]
#gi23 great to be starting the final day with sessions on #colorectalcancer &amp; #analcancer. and that too with an fda approval entering the clinic for the subset of her2 #crcsm. out for tucatinib tas-102+bev bot/bal tnt/organ preservation
&amp; #ctdna . 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO📍 #GI23